Charcot Foot: Warning Signs, Causes & Why Early

What Charcot foot is — and why it’s so dangerous

Charcot neuroarthropathy is a progressive degeneration of the bones and joints of the foot in patients with severe peripheral neuropathy. Despite being described by Jean-Martin Charcot in the 1860s, it remains one of the most under-recognized medical emergencies in primary care. The pathophysiology involves two overlapping mechanisms: neurovascular (loss of sympathetic tone causes hyperemia, which leaches calcium from the bone) and neurotraumatic (loss of protective sensation allows repeated unperceived micro-trauma to fracture the weakened bones).

The result: a foot that fragments and collapses from the inside while the patient walks on it normally — because they can’t feel it. By the time the deformity is visible to the patient, the damage is often advanced.

Who’s at risk: any patient with significant peripheral neuropathy. The vast majority are diabetic — about 0.3-13% of diabetics with neuropathy will develop Charcot in their lifetime, with higher rates in patients with longstanding poorly-controlled diabetes. Other causes include leprosy (worldwide), spinal cord injury, syphilis, alcoholic neuropathy, and rare hereditary neuropathies.

Recognizing acute Charcot — the early signs

Stage 0 (the “pre-radiographic” or “acute”) Charcot foot is what we want to catch. The classic findings:

• Sudden unilateral foot swelling — often dramatic
• Warm to touch — at least 4°F warmer than the opposite foot (use a digital skin thermometer if available)
• Redness — often diffuse, may resemble cellulitis
• Mild-to-moderate pain — often disproportionately less than the apparent severity. Some patients have no pain at all.
• Underlying severe neuropathy — Semmes-Weinstein monofilament negative
• Often preceded by minor trauma — a fall, a twist, an unaccustomed long walk — that the patient may not even remember

Critical differential diagnoses we must rule out:

• Cellulitis — also red, warm, swollen, but usually has more systemic signs (fever, elevated WBC), tracks along lymphatics, and improves rapidly with IV antibiotics. Charcot does not.
• Deep vein thrombosis — calf swelling, often less foot swelling, positive Wells score, confirmed with venous ultrasound.
• Gout — exquisitely painful (the opposite of Charcot’s relative painlessness), tophi may be visible, elevated uric acid.
• Osteomyelitis — usually has an associated wound or ulcer providing the portal of entry; bone scan/MRI helps differentiate.

The single most useful bedside finding: temperature difference between feet. A >4°F warmer affected foot in a diabetic with neuropathy strongly suggests Charcot. We track this throughout treatment as a sign of disease activity.

The Eichenholtz stages — and why early detection matters so much

Stage 0 — Acute (radiographically silent)

The foot is warm and swollen, but X-rays look normal. MRI can show bone marrow edema. This is the highest-yield treatment window. Immobilization here often prevents structural collapse entirely.

Stage 1 — Development / fragmentation

X-rays show bone fragmentation, joint dislocation, and debris. Foot is still hot and swollen. Treatment is immobilization; outcomes are very good if compliance is maintained.

Stage 2 — Coalescence

Inflammation begins to settle. Temperature gradient decreases. New bone formation visible on X-ray. Continued immobilization; gradual reintroduction of weight-bearing under cast/boot.

Stage 3 — Reconstruction / consolidation

Foot is cool, no longer swollen. Bones have re-modeled into whatever shape they ended up in. If detected early and properly immobilized, the foot retains good structure. If not, the rocker-bottom deformity is established.

Treatment — non-surgical and surgical pathways

Step 1: Total contact casting (or removable equivalent)

The cornerstone of Charcot treatment. A total contact cast (TCC) immobilizes the foot, redistributes pressure across the entire plantar surface, and protects the bones during their inflammatory phase. The cast is changed every 1-2 weeks; foot temperature is checked at each visit. Treatment continues until the temperature gradient between feet is <4°F and X-rays show consolidation — typically 3-4 months but sometimes longer.

For patients who can’t tolerate TCC (open wound, severe deformity, balance issues), removable alternatives include the CROW (Charcot Restraint Orthotic Walker) boot, the Bohler walking cast, or a custom AFO. Compliance is the biggest factor in outcome — and the published outcomes data suggests TCC has the best healing rates because patients can’t remove it.

Step 2: Complete non-weight-bearing (selected patients)

For severe Stage 0-1 Charcot or any patient with simultaneous open ulcer, strict non-weight-bearing in a knee scooter or wheelchair for 4-12 weeks dramatically improves outcomes. Less weight on the foot = less fragmentation. This is hard for patients to comply with, but worth the discussion in high-risk cases.

Step 3: Pharmacologic adjuncts (selected cases)

Bisphosphonates (such as IV pamidronate or oral risedronate) have shown some benefit in reducing the duration of the acute inflammatory phase in small RCTs. The evidence is mixed, and I use them selectively — typically in patients whose Charcot remains active beyond 4-6 months despite proper immobilization. They are not first-line.

Step 4: Surgical reconstruction (Stage 3 with established deformity)

For patients who present too late (already in established rocker-bottom deformity) or who develop recurrent ulcers despite custom CROW bracing, surgical reconstruction can restore plantigrade alignment. Modern reconstructive options:

• Exostectomy: Removing the bony prominence that’s ulcerating, without major realignment
• Midfoot fusion (TMT or Lisfranc) with plates and screws or beaming construct
• Hindfoot/ankle fusion with intramedullary nail — for severe ankle/hindfoot Charcot
• External fixation — when soft tissue won’t tolerate internal hardware

Surgical outcomes are improving but the operations are demanding — 3-6 months non-weight-bearing post-op, fusion rates of 75-85%, and re-operation rates of 15-30% in published series. For most patients, the goal is “plantigrade and braceable” rather than “normal looking.” A foot that can be safely fit into a CROW boot and used for daily activities is the realistic outcome.

Long-term management — preventing the next ulcer

Even after the acute Charcot has consolidated, the foot is permanently at higher risk for ulceration. Lifelong management includes:

• Custom CROW boot or Charcot Restraint Orthosis for any prolonged walking
• Custom diabetic shoes with extra-depth + custom inserts for daily wear (Medicare-covered)
• Podiatric exam every 1-3 months for life — these patients are IWGDF risk Category 3
• Daily self-inspection of both feet, especially at the apex of any deformity (rocker-bottom midfoot area)
• Glycemic control optimization — A1c <8% reduces re-activation risk
• Smoking cessation — improves bone density and wound-healing capacity